Assessing the Impact of Jail-Initiated Medication for Opioid Use Disorder: A Multisite Analysis of the SOMATICS Collaborative
Objective
The objective of this study was to assess the effects of jail-initiated medication for opioid use disorder (MOUD) and patient navigation (PN) on opioid use disorder (OUD) at 6 months post-release.
Study Details
Three randomized trials (combined N = 330) were conducted to evaluate whether MOUD initiated prior to release from jail, with or without PN, would reduce the likelihood of an OUD diagnosis 6 months post-release compared to enhanced treatment-as-usual (ETAU).
Findings
Results showed that MOUD initiation compared to ETAU was not associated with an OUD diagnosis at 6 months post-release (69% vs. 75%, OR = 0.67, 95% CI: 0.42 to 1.20). Similarly, PN compared to MOUD without PN was not associated with an OUD diagnosis (63% vs 77%, OR = 0.61, 95% CI: 0.27 to 1.53).
Implications
The study highlights the need to improve the effectiveness of MOUD for patients starting treatment in jail, particularly focusing on post-release treatment adherence.
Practical Solutions and Value
Clinical trials play a crucial role in developing safe and effective treatments. Our AI-driven platform, DocSym, consolidates ICD-11 standards, clinical protocols, and research, making it easier for clinicians to access essential knowledge. Additionally, our mobile apps support scheduling, treatment monitoring, and telemedicine, streamlining operations and expanding digital services to enhance patient care and outcomes.
AI integration in clinics can improve workflows, reduce paper routines, and ultimately benefit patient outcomes. Learn more about how we can help at aidevmd.com.
